)
NEWS
Media Contacts:
Europe
Emmanuella Dekonor
Mobile: +44 7920500496
Email: Emmanuella.Dekonor@seqirus.com
United States
Polina Miklush
Mobile: +1 908 608 7170
Email: polina.miklush@seqirus.com
Asia Pacific
Joanne Cleary
Mobile: +61 428 816 751
Email: Joanne.Cleary@seqirus.com
Seqirus news releases
Seqirus news releases
• Appoints Roberta Duncan as new program lead to drive technology advancement
• Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza
The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic.
First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.
This news release is intended for Health Professional media only.
Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year
The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza vaccines on schedule, across Europe
CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19 vaccine candidate (V451), and a separate HoA with AstraZeneca to manufacture the Oxford University candidate (AZD1222), should clinical trials of both prove successful.
This news release is intended for medical, pharmaceutical industry and business media
Partnership brings together world-leading plasma companies to focus on developing and delivering a hyperimmune immunoglobulin in the global fight against COVID-19
This news release is intended for medical and pharmaceutical trade media and financial media only
To speed treatments, global biotech leader CSL offers to lend the company’s expertise in science and manufacturing.
Study highlights lower hospitalization rates in adults 65 years and older living in U.S. nursing homes who received an adjuvanted influenza vaccine versus standard trivalent influenza vaccine (TIV)
The Executive Order represents a significant step towards accelerating access to more effective technologies, such as cell-based platforms, immunity-enhancing adjuvants, and other innovative approaches.